Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study

Nørgård, B.; Fonager, K.; Pedersen, L.; Jacobsen, B.A.; Sørensen, H.T.
February 2003
Gut;Feb2003, Vol. 52 Issue 2, p243
Academic Journal
Background: 5-Aminosalicylic acid (5-ASA) preparations are the firstline drugs in the treatment of inflammatory bowel disease. Data on the safety of these drugs in pregnancy are sparse. Aims: To examine the risk of adverse birth outcome in women who were prescribed 5-ASA drugs during pregnancy. Patients: Women were included in the study if they were prescribed 5-ASA drugs immediately before or during pregnancy. To examine the risk of malformations, we included 60 pregnancies exposed to 5-ASA drugs 30 days before pregnancy or in the first trimester. To examine stillbirths, preterm births, and Iow birth weight, we included 88 pregnancies exposed during the entire pregnancy. Outcomes were compared with those of 19 418 pregnancies in which no drugs were prescribed for mothers during the study period. Methods: We conducted a Danish cohort study based on data from a population based prescription registry, the Danish Birth Registry, and the Hospital Discharge Registry in North Jutland County. Results: Odds ratios for malformations, stillbirth, preterm birth, and Iow birth weight in women who received prescriptions for 5-ASA drugs were 1.9 (95% confidence interval 0.7-5.4), 6.4 (1.7-24.9), 1.9 (0.9-3.9), and 1.2 (0.4-3.3), respectively. The increased risk of stillbirth and preterm birth were found only in patients with ulcerative colitis. Conclusions: We found an increased risk of stillbirth and preterm birth in women who had been prescribed 5-ASA drugs during pregnancy but no substantial increased risk of malformations. It was difficult to distinguish the specific effects of disease activity and 5-ASA drugs.


Related Articles

  • Inflammatory bowel disease in pregnancy. Alstead, E.M.; Nelson-Piercy, C. // Gut;Feb2003, Vol. 52 Issue 2, p159 

    Discusses inflammatory bowel disease (IBD) pregnancy. Increased rick for small or premature babies; Normal outcome of pregnancy; Reactions of drugs used to treat IBD; Need for further studies to help in the difficult decisions about the management of IBD during the time of conception and pregnancy.

  • Outcomes of infants born to mothers with inflammatory bowel disease: a population-based cohort study. Dominitz, Jason A.; Young, Josephine C.C.; Boyko, Edward J. // American Journal of Gastroenterology;Mar2002, Vol. 97 Issue 3, p641 

    OBJECTIVE:Limited population-based data on inflammatory bowel disease (IBD) and pregnancy outcomes exist. The purpose of this study is to determine the association between maternal IBD status and adverse pregnancy outcomes.METHODS:Using computerized birth records of infants born to mothers with...

  • Inflammatory bowel disease in pregnancy. Balzola, Federico; Bernstein, Charles; Ho, Gwo-Tzer; Russell, Richard K. // Inflammatory Bowel Disease Monitor;2011, Vol. 12 Issue 2, p80 

    The article examines the impact of inflammatory bowel disease on pregnancy outcomes, including the association of disease activity at conception with preterm births, fetal loss, and low birth weight.

  • Inflammatory bowel disease during pregnancy raises the risk of fetal problems.  // Modern Medicine;Feb98, Vol. 66 Issue 2, p38 

    Discusses the abstract `Pregnancy Outcomes in Women With Inflammatory Bowel Disease--a Population-Based Cohort Study,' by D. Kornfeld, S. Cnattingius and A. Ekbom, which appeared in the October 1997 issue of `American Journal of Obstetrics & Gynecology.'

  • Elections, health reform and rationing.  // Obstetric Medicine (1753-495X);Jun2010, Vol. 3 Issue 2, p47 

    An introduction to the journal is presented in which the editor discusses an article on the changes in a psychiatric antenatal clinic by N. Shah, breast cancer in pregnancy by Rita Sasidharan, and the management of inflammatory bowel disease in pregnancy by M. A. Smith J. D. Sanderson.

  • IBD Medication Use in Pregnancy: A Review of Evidence For and Against. Hwang, Caroline; Mahadevan, Uma // Inflammatory Bowel Disease Monitor;2011, Vol. 12 Issue 2, p47 

    Women with IBD are able to conceive at the same rate as women without IBD, but with an increased risk of adverse events. The biggest risk to pregnancy outcome, aside from a diagnosis of IBD, is disease activity. Therefore, continuing medications to maintain remission is important. Most IBD...

  • The Effect on the Fetus of Medications Used to Treat Pregnant Inflammatory Bowel-Disease Patients. Moskovitz, David Norman; Bodian, Carol; Chapman, Mark L.; Marion, James F.; Rubin, Peter H.; Scherl, Ellen; Present, Daniel H. // American Journal of Gastroenterology;Apr2004, Vol. 99 Issue 4, p656 

    OBJECTIVES: We reviewed data to investigate the effect of 5-ASA drugs, metronidazole, ciprofloxacin, prednisone, 6-mercaptopurine, azathioprine, and cyclosporine on pregnancy outcomes in patients with inflammatory bowel disease (IBD).METHODS: One hundred and thirteen female patients with a total...

  • Inflammatory bowel disease in pregnancy: a review. Miller, J. P. // Journal of the Royal Society of Medicine;Apr1986, Vol. 79 Issue 4, p221 

    The article discusses on the effect of pregnancy on the course of inflammatory bowel disease. According to research, there is little evidence that pregnancy exerts only little evidence on the matter. Patients, however, should be advised to conceive when in remission if possible, because those...

  • What's Good for the Goose Should Be Good for the Gander -- 6-MP Use in Fathers With Inflammatory Bowel Disease. Kane, Sunanda V. // American Journal of Gastroenterology;Mar2000, Vol. 95 Issue 3, p581 

    Presents a study on the outcome of pregnancies when fathers are treated with 6-mercaptopurine (6-MP) for inflammatory disease. Risks of using 6-MP in treating inflammatory disease during pregnancy; Methods used in the experiment; Study findings.


Read the Article


Sign out of this library

Other Topics